Clinical Guide for Management of MMM (Myositis-Myocarditis-Myasthenia Gravis) Overlap Syndrome Evidence-Based Guide for Healthcare Professionals
Based on: Furlepa et al. (2025) Cancers
and Sánchez-Camacho et al. (2025) Frontiers in Immunology
10 KEY TAKEAWAY POINTS
1. High
Mortality, Rapid Onset
MMM syndrome is a life-threatening immune-related adverse event with
38-60% in-hospital mortality. Median onset is 21 days (range: 2-6
weeks) after immune checkpoint inhibitor (ICI) initiation, requiring immediate
recognition and aggressive treatment[32][33].
2. Triple
Screening is Mandatory
When one component is suspected, screen for all three conditions
simultaneously. Up to 76.2% of patients had screening for all components on
admission. Early troponin and CK levels are critical—89.7% had elevated CK
(>600 U/L) and 100% had elevated troponin[32][33].
3. Corticosteroids
Are Universal First-Line
100% of patients receive
corticosteroids, but dosing varies widely. ESMO/ASCO guidelines recommend:
•
Mild (Grade 2): Prednisone 0.5 mg/kg/day
•
Severe (Grade 3-4): Methylprednisolone 1-2 mg/kg/day or pulse therapy 500-1000 mg/day ×
3-5 days[34][39]
4. Early
IVIG Prevents Myasthenic Crisis
Concurrent IVIG with steroids (rather
than waiting for steroid failure) may prevent the “myasthenic dip”—worsening MG
symptoms within 10 days of steroid initiation. Weaver et al. reported only
10% mortality with early IVIG (1-2 g/kg over 5 days) for MGFA Class
≥II[33][44].
5. Steroid-Induced
Myasthenic Deterioration is Common
57.4% of patients experienced worsening myasthenia after steroids alone, with 66.6% requiring ventilatory support.
Neurologists recognize this phenomenon; oncologists may not. Consider prophylactic
IVIG or PLEX alongside steroids[32][33].
6. ICU
Admission and Respiratory Support Are Frequent
66.7% required ICU admission, with 73.5%
needing ventilatory support (mechanical ventilation or NIV). Respiratory
failure from myasthenia gravis is the leading cause of death. Early
respiratory monitoring and low threshold for ICU transfer are
essential[32].
7. Cardiac
Conduction Abnormalities Require Vigilance
40% develop arrhythmias, including
complete heart block. 25% developed complete heart block during
hospitalization, and 15.9% required permanent pacemakers. Continuous
telemetry and cardiology involvement are mandatory[32][33][34].
8. Targeted
Second-Line Agents Improve Outcomes
•
Abatacept + ruxolitinib for myocarditis-predominant disease (reduced mortality from 60% to
3% in one series)[33][51][53]
•
Rituximab for antibody-mediated disease (anti-AChR, anti-titin positive)[33]
•
Tocilizumab for IL-6-driven inflammation (myositis/myocarditis)[33][62]
•
Avoid infliximab in heart
failure (contraindicated)[56][62]
9. Plasma
Exchange Timing Matters
PLEX used shortly after IVIG may remove therapeutic
immunoglobulins, negating benefit. If using both, administer PLEX first
or ≥4 weeks after IVIG. PLEX efficacy in MMM is questionable—may be most
effective when used early rather than as rescue therapy[32][33].
10. ICI Rechallenge is Contraindicated
MMM syndrome follows a monophasic
course with minimal relapse (3 relapses in 82 cases), but ICI must be
permanently discontinued. The risk of recurrence with rechallenge far
outweighs oncologic benefit. Multidisciplinary discussion is required for
alternative cancer therapies[32][33].
CLINICAL GUIDE
SECTION 1:
EPIDEMIOLOGY AND PATHOPHYSIOLOGY
Incidence
•
0.1-0.3% of patients on ICI
therapy[33]
•
Most common with PD-1
inhibitors (pembrolizumab, nivolumab)
•
Higher risk with combination
therapy (CTLA-4 + PD-1): 0.28% vs 0.06% monotherapy[34]
•
Male predominance (65.1%), median age 72 years[32]
Underlying Mechanisms
1.
T-cell mediated inflammation: CD8+ T-cell infiltration of myocardium, skeletal muscle, and
neuromuscular junction[33]
2.
Complement activation: C5b-9 deposits in muscle biopsies; C4d in cardiac tissue[33]
3.
Autoantibody formation: Pre-existing anti-AChR or anti-titin antibodies may predispose to
MMM[33][40]
4.
Molecular mimicry: Shared antigens between myocyte, cardiomyocyte, and neuromuscular
junction[33]
Risk Factors
•
Pre-existing autoimmune
disease[34]
•
Positive autoantibodies
(anti-AChR, anti-titin) before ICI[33][40]
•
Combination ICI therapy[34]
•
Melanoma, renal cell carcinoma,
lung cancer (most common malignancies)[32]
SECTION 2: CLINICAL PRESENTATION
Symptom Onset
•
Median: 21 days after ICI initiation (range: 14-42 days)[32][33]
•
Can occur as early as 2
weeks or as late as >8 weeks
•
Symptoms are rapidly
progressive, often requiring ICU admission within 24-72 hours
Cardinal Symptoms by
Component
Myositis:
•
Proximal muscle weakness
(difficulty standing, raising arms)
•
Myalgia (may be absent in
severe cases)
•
Neck extensor weakness
(characteristic finding)
•
CK elevation (median >2000
U/L, range 485-4157 U/L)[33]
Myocarditis:
•
Chest pain, dyspnea,
palpitations
•
Arrhythmias (complete heart block most concerning)
•
Hypotension, cardiogenic shock
(severe cases)
•
Troponin elevation (100% of
cases): cTnI >40 ng/L or cTnT >10 ng/L[32][33]
•
ECG abnormalities: 57.5% had
conduction abnormalities (RBBB, LBBB, AV block)[32]
Myasthenia
Gravis (irMG):
•
Bilateral ptosis (most common, >90% of cases)[33]
•
Diplopia, ophthalmoplegia
•
Bulbar dysfunction: Dysphagia, dysphonia, rhinolalia
•
Respiratory failure (requires intubation in severe cases)
•
Fatigable weakness (improves
with rest)
•
MGFA Classification[52][55][61]:
–
Class I: Ocular only
–
Class II: Mild generalized weakness
–
Class III: Moderate generalized weakness
–
Class IV: Severe generalized weakness
–
Class V: Intubation/mechanical ventilation
Red Flags
Requiring Immediate ICU Transfer
•
Respiratory distress, declining
oxygen saturation
•
Bulbar symptoms (dysphagia,
aspiration risk)
•
Complete heart block,
ventricular arrhythmias
•
Hypotension, signs of
cardiogenic shock
•
Rapidly ascending weakness
SECTION 3: DIAGNOSTIC WORKUP
Initial
Screening (Within 48 Hours of Presentation)
Laboratory Tests:
1.
Creatine Kinase (CK): >600 U/L abnormal (sensitivity 89.7%)[32]
2.
Cardiac troponin I or T: Troponin T more sensitive than Troponin I[32][33]
3.
Transaminases: May be elevated due to muscle breakdown (not hepatitis)
4.
Complete blood count,
metabolic panel
Cardiac Evaluation:
1.
12-lead ECG (repeat every 6-12 hours initially)
–
Conduction abnormalities in 57.5%[32]
–
New bundle branch blocks, AV
blocks, QT prolongation
2.
Continuous telemetry (mandatory for all suspected cases)
3.
Troponin (repeat serially to assess trajectory)
4.
Echocardiography (early, within 48 hours)
–
Often normal in early stages
(preserved LVEF in majority)
–
Look for wall motion
abnormalities, pericardial effusion
5.
Cardiac MRI (within 7-10 days, if stable)
–
Modified Lake Louise
Criteria[51][54]
–
Interstitial edema, late
gadolinium enhancement
–
Gold standard for myocarditis diagnosis
ESC-ICOS Diagnostic Criteria for ICI-Induced Myocarditis[51][60]:
•
Troponin elevation (mandatory)
•
PLUS one major criterion:
–
Diagnostic cardiac MRI (Lake
Louise 2/2)
•
OR two or more minor
criteria:
–
Clinical symptoms (chest pain,
dyspnea)
–
New ECG abnormalities
–
Decline in LVEF on echo
–
Suggestive cardiac MRI
–
Presence of other
immune-related adverse events (myositis, MG)
Neuromuscular Evaluation:
1.
Autoantibody panel:
–
Anti-AChR antibodies: Positive in 42.2% of MMM cases[32]
–
Anti-titin antibodies: Positive in 5/82 cases[32]
–
Anti-MuSK antibodies (rare)
–
Anti-Kv1.4, anti-ryanodine
(sporadic reports)
2.
Electromyography (EMG):
–
Myopathic changes (70.5%
sensitivity when performed)[32]
–
Repetitive nerve stimulation:
Decremental response in 31.3%[32]
3.
Muscle MRI (if diagnosis unclear)
4.
Muscle biopsy (consider if diagnosis uncertain or steroid-refractory)
–
CD8+ T-cell infiltration,
myonecrosis[33]
Differential Diagnosis
Myositis:
•
Rhabdomyolysis, statin myopathy
•
Polymyalgia rheumatica
•
Paraneoplastic necrotizing
myopathy
Myocarditis:
•
Acute coronary syndrome (rule
out with angiography if indicated)
•
Heart failure from other causes
•
Takotsubo cardiomyopathy
•
Infectious myocarditis
Myasthenia
Gravis:
•
Lambert-Eaton myasthenic
syndrome (LEMS): Improves with exercise, EMG shows facilitation
•
Guillain-Barré syndrome (GBS):
Ascending weakness, sensory changes, albuminocytologic dissociation in
CSF[34][48]
•
Brainstem stroke, myasthenia
crisis from other causes
SECTION 4: MANAGEMENT PROTOCOL
Immediate Actions (Hour 0)
1.
Discontinue ICI immediately
and permanently[32][33][34]
2.
Admit to ICU or
high-dependency unit for:
–
Continuous cardiac telemetry
–
Frequent vital signs, oxygen
saturation monitoring
–
Respiratory assessment (FVC,
NIF if available)
3.
Multidisciplinary team
activation:
–
Cardiology, Neurology,
Rheumatology/Immunology, Oncology, Critical Care
4.
Hold acetylcholinesterase
inhibitors until cardiac stability confirmed
–
Pyridostigmine can cause
bradycardia, hypotension, worsening heart block[32]
–
Reintroduce cautiously once
conduction abnormalities stabilized
FIRST-LINE THERAPY (Day 0-3)
1.
High-Dose Corticosteroids (100% of patients receive)[32][33][34]
ESMO/ASCO
Guideline Dosing[34][39]:
•
Grade 2 (Mild): Prednisone 0.5 mg/kg/day PO
•
Grade 3-4 (Moderate-Severe):
–
Methylprednisolone 1-2
mg/kg/day IV (standard dose)
–
OR Pulse therapy: 500-1000
mg/day IV × 3-5 days (preferred for severe cases,
myocarditis-predominant)[33]
–
Followed by taper to 1
mg/kg/day, then slow taper over 3-6 months
Clinical
Practice from Case Series[32][33]:
•
Furlepa et al.: Doses ranged from 75-1250 mg/day (prednisolone-equivalent)
•
Sánchez-Camacho et al.: All 4 patients received high-dose methylprednisolone (500-1000
mg/day × 3-5 days)
Monitoring:
•
Blood glucose (risk of
hyperglycemia)
•
Bone protection: Calcium,
vitamin D, bisphosphonates if prolonged
•
GI prophylaxis: Proton pump
inhibitor
•
Antimicrobial prophylaxis:
Consider PJP prophylaxis (trimethoprim-sulfamethoxazole) if CD4 <200 or
prolonged high-dose steroids
⚠️ CRITICAL
WARNING: Myasthenic Dip
•
56% of patients worsened after steroids alone[32]
•
Transient worsening of MG
symptoms within 10 days of steroid initiation[32][33]
•
66% required ventilatory
support[32]
•
Mitigation strategy: Concurrent IVIG or PLEX (see below)
2.
Acetylcholinesterase Inhibitors (for irMG)[33][34]
•
Pyridostigmine: 30-60 mg PO every 6-8 hours
–
Titrate based on response (max
120 mg every 3-4 hours)
–
Hold if:
•
Heart rate <60 bpm
•
New/worsening AV block
•
Hypotension
•
QT prolongation
•
Alternative: Neostigmine (IV if unable to take PO)
Note: 3 patients developed new cardiac conduction deficits after AChEI
initiation[32]. Use with extreme caution.
3.
Supportive Care
•
Oxygen therapy as needed
•
Non-invasive ventilation
(NIV) for impending respiratory failure
–
Low threshold for intubation
if:
•
FVC <20 mL/kg
•
NIF <30 cm H₂O
•
Inability to protect airway
(bulbar weakness)
•
Temporary pacemaker if high-grade AV block
•
Vasopressor support if cardiogenic shock
•
DVT prophylaxis (mechanical if thrombocytopenia; pharmacologic if safe)
SECOND-LINE
THERAPY (Day 3-7 if No Improvement or Early Addition for MGFA Class ≥II)
Decision Point: Assess clinical response
at 48-72 hours
•
Improving: Continue steroids,
taper gradually
•
No improvement or worsening:
Add second-line therapy immediately
1. Intravenous Immunoglobulin (IVIG)[32][33][34][44]
Dosing:
•
2 g/kg total dose divided over 3-5 days (e.g., 0.4 g/kg/day × 5 days)
•
Used in 65.9% of patients
in Furlepa series[32]
•
52% received as part of
first-line therapy alongside steroids[32]
Evidence:
•
Weaver et al.: 10% mortality when IVIG given early (within 10 days) with steroids
for MGFA Class ≥II[33][44]
•
Prevents myasthenic dip from isolated corticosteroids[33]
Indications for Early IVIG (concurrent
with steroids):
•
MGFA Class II or higher (any generalized weakness)[33][44][52][61]
•
Bulbar symptoms present
•
Rapidly progressive weakness
•
Age >65 years, comorbidities
(reduced tolerance for respiratory failure)
Contraindications:
•
IgA deficiency (risk of
anaphylaxis)
•
Renal insufficiency
(sucrose-containing formulations)
•
Hypercoagulable state
(relative)
Adverse Effects:
•
Headache, aseptic meningitis
•
Hemolysis, renal dysfunction
•
Thromboembolism (0.5-4%)
2. Plasma Exchange (PLEX)[32][33][34]
Dosing:
•
5 sessions over 7-10 days (alternate days)
•
Volume exchanged: 1-1.5 plasma
volumes per session
•
Used in 32.9% of patients[32]
Clinical Context:
•
Equivalent efficacy to IVIG for myasthenia gravis in classical MG studies
•
Timing matters: If using both IVIG and PLEX:
–
PLEX first, then IVIG (preferred sequence)
–
OR PLEX ≥4 weeks after IVIG
(avoid removing therapeutic immunoglobulins)[32]
•
In 4 cases where PLEX
was given shortly after IVIG, potential negative interaction[32]
Indications:
•
Steroid-refractory myasthenia
(MGFA IV-V)
•
Antibody-mediated disease
(anti-AChR positive)
•
Severe disease requiring rapid
onset (faster than IVIG: 1-2 days vs 3-5 days)
Contraindications:
•
Hemodynamic instability
(relative; can use with caution)
•
Active infection/sepsis
•
Coagulopathy
Adverse Effects:
•
Central line complications
(infection, thrombosis, pneumothorax)
•
Hypotension during exchanges
•
Citrate toxicity (hypocalcemia,
paresthesias)
•
Depletion of clotting factors,
immunoglobulins
3. Tocilizumab (IL-6 Receptor Inhibitor)[33][62]
Dosing:
•
8 mg/kg IV (single dose or repeat every 2 weeks)
–
Maximum 800 mg/dose
•
Can transition to subcutaneous
162 mg weekly after stabilization[33]
Mechanism: Blocks IL-6, implicated in
ICI-myositis and myocarditis pathophysiology[33][62]
Evidence from Case Series:
•
Sánchez-Camacho et al.:
–
Case 1: Single dose
tocilizumab, died (refractory disease)
–
Case 2: Two IV doses →
transitioned to SC → cTnI normalized, patient asymptomatic[33]
–
Case 4: Single dose tocilizumab
→ improved CK/cTnT, patient stabilized[33]
Indications:
•
Steroid-refractory myositis or
myocarditis
•
Persistent troponin elevation
despite steroids + IVIG
•
IL-6 elevation (if available)
Adverse Effects:
•
Increased infection risk
•
Hepatotoxicity (monitor
transaminases)
•
GI perforation (rare)
•
Neutropenia, thrombocytopenia
THIRD-LINE
THERAPY (Day 7+ if Refractory to First- and Second-Line)
Definition of Refractory Disease:
•
No clinical improvement after 7
days of steroids + IVIG/PLEX
•
Progressive respiratory failure
or cardiogenic shock despite treatment
•
Steroid-dependent with
inability to taper
1. Abatacept + Ruxolitinib (for Myocarditis-Predominant
Disease)[33][51][53][59][62][68]
Rationale:
•
CTLA-4 haploinsufficiency may predispose to ICI-myocarditis
•
Abatacept (CTLA-4-Ig fusion protein): Restores CTLA-4 blockade, inhibits
T-cell co-stimulation
•
Ruxolitinib (JAK1/2 inhibitor): Rapidly suppresses T-cell activation and
cytokine signaling
Dosing:
•
Abatacept: 10 mg/kg IV on Days 1, 15, 29, then monthly[33][53]
•
Ruxolitinib: 10 mg PO twice daily[33][53]
Evidence:
•
Salem et al. (2019): Mortality reduced from 60% to 3% in 40-patient series with
abatacept + ruxolitinib[33][51]
•
Indications:
–
Severe myocarditis with LVEF
<40%
–
Cardiogenic shock
–
Steroid-refractory disease
–
High-grade AV block
Adverse Effects:
•
Profound immunosuppression (PJP
prophylaxis mandatory)
•
Reactivation of latent
infections (TB, hepatitis B)
•
Cytopenias (ruxolitinib)
Contraindications:
•
Active infection (relative;
balance risk vs benefit)
•
Severe immunodeficiency
2. Rituximab (for Antibody-Mediated Disease)[33][62]
Dosing:
•
375 mg/m² IV weekly × 4
weeks[33]
•
Alternative: 1000 mg IV on Days
1 and 15
Mechanism: CD20+ B-cell depletion →
reduces autoantibody production
Evidence from Case Series:
•
Sánchez-Camacho et al., Case
3:
–
Patient with anti-titin
antibodies in serum and CSF
–
Worsened on Day 20 despite
steroids + PLEX
–
Rituximab 375 mg/m² weekly ×
4 weeks → rapid clinical improvement after first
dose
–
Discharged Day 25, full
recovery from myositis, partial recovery from irMG (minimal residual
diplopia)[33]
Indications:
•
Anti-AChR antibody positive (42.2% of MMM cases)[32]
•
Anti-titin antibody positive (predictor of severity)[32][33]
•
Steroid-refractory myasthenia
gravis
•
Failed IVIG/PLEX
Adverse Effects:
•
Infusion reactions (premedicate
with antihistamines, acetaminophen)
•
Prolonged B-cell depletion
(6-12 months)
•
Increased infection risk
(consider IVIG replacement if recurrent infections)
•
Progressive multifocal
leukoencephalopathy (PML, rare)
3. Mycophenolate Mofetil (MMF)[32][34][62]
Dosing:
•
500-1000 mg PO twice daily
•
Titrate based on tolerance and
response
Mechanism: Inhibits inosine
monophosphate dehydrogenase → blocks T- and B-cell proliferation
Evidence:
•
Most commonly used
second-line agent in Furlepa series: 51.2%
(21/41 patients)[32]
•
Used for steroid-refractory
myositis, myocarditis, hepatitis
Indications:
•
Steroid-sparing agent (allow
steroid taper)
•
Maintenance immunosuppression
after acute phase
•
Steroid-refractory disease
(adjunct to other agents)
Adverse Effects:
•
GI upset (diarrhea,
nausea)—dose-limiting
•
Bone marrow suppression
(leukopenia)
•
Increased infection risk
4. Other Agents (Limited Data)[32][56][62]
Infliximab (TNF-α Inhibitor):
•
19.5% of patients[32]
•
⚠️ CONTRAINDICATED in
moderate-severe heart failure[56][62]
•
Use with caution in MMM
(conflicting recommendations)
•
Dosing: 5 mg/kg IV at Weeks 0,
2, 6
•
Avoid in
myocarditis-predominant cases
Anti-thymocyte Globulin (ATG):
•
Profound T-cell depletion
•
Reserved for life-threatening,
refractory cases
•
High infection risk
Alemtuzumab (Anti-CD52):
•
Case reports of efficacy[62]
•
Profound, prolonged lymphocyte
depletion
Eculizumab/Ravulizumab (Complement Inhibitors):
•
For complement-mediated MMM
(C5b-9 deposits on biopsy)[33][35]
•
Case reports of response in
refractory cases
SECTION 5:
MONITORING AND SUPPORTIVE CARE
Acute Phase (Days 0-14)
Daily Clinical
Assessment:
•
Vital signs every 4 hours
•
Neurologic exam: Ptosis,
diplopia, bulbar function, limb strength
•
Cardiac: Telemetry review,
daily ECG
•
Respiratory: Oxygen saturation,
work of breathing, FVC (if feasible)
Laboratory
Monitoring:
•
Daily (Days 0-7):
–
Troponin (trend to assess
myocarditis resolution)
–
CK (trend to assess myositis
resolution)
–
Electrolytes, renal function
(especially if on PLEX)
•
Every 2-3 days (Days 7-14):
–
Troponin, CK (if improving)
–
CBC (if on immunosuppressants)
–
Liver function tests
Cardiac
Monitoring:
•
Continuous telemetry until troponin normalized and no arrhythmias × 48 hours
•
Repeat ECG:
–
Daily (Days 0-3)
–
Every 2-3 days (Days 4-14)
•
Repeat echocardiography at Day 7-10 (assess for worsening LVEF, new wall motion
abnormalities)
Respiratory
Monitoring:
•
FVC and NIF every 8-12 hours if bulbar symptoms or respiratory complaints
•
Intubation criteria:
–
FVC <20 mL/kg or <1 L
–
NIF <30 cm H₂O
–
pCO₂ >50 mmHg with
respiratory acidosis
–
Inability to protect airway
Subacute Phase (Weeks 2-12)
Corticosteroid
Taper:
•
Begin taper once:
–
Clinical improvement (strength
improving, no new symptoms)
–
Troponin downtrending or
normalized
–
CK <2× ULN
•
Taper schedule (example):
–
Week 2-4: Reduce by 10 mg/week
(if on prednisone 60 mg/day → 40 mg → 20 mg)
–
Week 4-8: Reduce by 5 mg/week
(20 mg → 10 mg)
–
Week 8-12: Reduce by 2.5
mg/week (10 mg → 5 mg)
–
Month 3-6: Reduce by 1 mg/week
to discontinuation
•
Monitor for relapse: 3M symptoms recurred with steroid weaning in several cases[32]
Transition
to Maintenance Immunosuppression (if needed):
•
Indications:
–
Inability to taper steroids
without symptom recurrence
–
Steroid-related toxicity
(diabetes, osteoporosis, myopathy)
•
Options:
–
Mycophenolate mofetil 500-1000
mg BID
–
Azathioprine 1-2 mg/kg/day
(slower onset)
–
Tocilizumab subcutaneous 162 mg
weekly (if myocarditis/myositis-predominant)
Follow-Up
Assessments:
•
Week 4:
–
Clinical exam
–
Troponin, CK, CBC, CMP
–
ECG
–
Echocardiography (if abnormal
at baseline)
•
Week 8-12:
–
Repeat troponin, CK
–
Cardiac MRI (assess for
residual myocarditis)
–
Consider repeat EMG if
persistent weakness
Long-Term Follow-Up
(Months 3-12)
Surveillance
for Late Effects:
•
Cardiac: Annual echocardiography, ECG (risk of chronic cardiomyopathy)
•
Respiratory: Pulmonary function tests if prolonged ventilation
•
Endocrine: Screen for adrenal insufficiency during steroid taper (morning
cortisol, ACTH stimulation test if symptoms)
•
Bone health: DEXA scan at 1 year if prolonged corticosteroids
Relapse
Monitoring:
•
3 relapses reported in 82
cases (3.7%)[32]
•
Symptoms: Recurrent ptosis,
weakness, dyspnea during steroid taper
•
Management: Increase steroids,
resume second-line therapy
Oncologic
Considerations:
•
ICI rechallenge is
contraindicated[32][33]
•
Multidisciplinary tumor board
discussion for alternative systemic therapies:
–
Targeted therapy (if actionable
mutations: BRAF, EGFR, ALK)
–
Chemotherapy
–
Clinical trials of non-ICI
agents
•
Caution with future
immunosuppression: Risk of cancer progression vs 3M
relapse
SECTION 6: GUIDELINE INTEGRATION
ESMO 2022 Guidelines[39]
Myocarditis:
•
Grade 2: Hold ICI, methylprednisolone 1-2 mg/kg/day, cardiology consult
•
Grade 3-4: Permanently discontinue ICI, methylprednisolone 500-1000 mg/day ×
3-5 days, ICU admission
•
Second-line: Infliximab, ATG, or mycophenolate (no specific recommendation for
abatacept)
Myositis:
•
Grade 2: Hold ICI, prednisone 1 mg/kg/day
•
Grade 3-4: Permanently discontinue ICI, methylprednisolone 1-2 mg/kg/day
•
Second-line: IVIG, PLEX, or immunosuppressants
Myasthenia
Gravis:
•
Grade 2: Hold ICI, prednisone 0.5-1 mg/kg/day, pyridostigmine
•
Grade 3-4: Permanently discontinue ICI, methylprednisolone 1-2 mg/kg/day,
IVIG or PLEX
•
Second-line: Rituximab, mycophenolate
⚠️ Gap in ESMO
Guidelines:
•
No specific guidance for MMM
overlap syndrome
•
No mention of early IVIG to
prevent myasthenic dip
•
Limited discussion of targeted
agents (abatacept, ruxolitinib, tocilizumab)
ASCO 2021 Guidelines[34]
General
Principles:
•
Hold ICI for most Grade 2
toxicities; resume when ≤Grade 1
•
Permanently discontinue for
Grade 3-4 cardiac, neurologic, or muscular toxicities
•
Corticosteroids: First-line for Grade 2-4 toxicities
•
IVIG: For steroid-refractory neurologic or hematologic toxicities
Cardiovascular
Toxicities:
•
High suspicion for myocarditis
if troponin elevated + symptoms
•
Continuous telemetry, early
cardiology involvement
•
Treatment:
–
Methylprednisolone 1-2
mg/kg/day
–
Consider infliximab, ATG, or
mycophenolate for refractory cases
•
No mention of abatacept or
ruxolitinib
Musculoskeletal
Toxicities:
•
Myositis: Hold ICI, steroids,
IVIG/PLEX for severe cases
•
Note: ASCO recognizes concomitant myocarditis and/or myasthenia
gravis has ominous prognosis with high mortality[34]
NCCN 2024 Guidelines[35][38]
Immunotherapy-Related
Toxicities:
•
Comprehensive guidance on ICI
toxicity management
•
Recent updates: Emphasis on emerging toxicities (myocarditis, overlap syndromes)
•
Monitoring: Weekly visits for combination ICI; every 2-3 weeks for monotherapy
•
Steroid prophylaxis: Bone protection, PJP prophylaxis if indicated
International
Cardio-Oncology Society (IC-OS) 2022 Guidelines[51][54][60]
Diagnostic Criteria for ICI-Myocarditis:
•
Troponin elevation (mandatory)
•
PLUS one major criterion:
–
Diagnostic cardiac MRI (Lake
Louise criteria 2/2)
•
OR two or more minor
criteria:
–
Clinical symptoms
–
New ECG abnormalities
–
Decline in LVEF
–
Suggestive cardiac MRI
–
Presence of other irAEs
(myositis, MG)
Treatment:
•
High-dose steroids first-line
•
Consider abatacept for
refractory cases
Myasthenia
Gravis Foundation of America (MGFA) Classification[52][55][61][64]
Clinical Classification (guides
treatment intensity):
•
Class I: Ocular weakness only
–
Prognosis: Excellent
–
Treatment: Pyridostigmine, may
not need steroids
•
Class II: Mild generalized weakness
–
IIa: Predominantly limb/axial
–
IIb: Predominantly bulbar/respiratory
–
Treatment: Pyridostigmine +
prednisone; consider IVIG
•
Class III: Moderate generalized weakness
–
IIIa: Predominantly limb/axial
–
IIIb: Predominantly bulbar/respiratory
–
Treatment: Steroids + IVIG/PLEX
•
Class IV: Severe generalized weakness
–
IVa: Predominantly limb/axial
–
IVb: Predominantly bulbar/respiratory (includes feeding tube)
–
Treatment: High-dose steroids +
IVIG/PLEX, ICU monitoring
•
Class V: Intubation/mechanical ventilation
–
Myasthenic crisis
–
Treatment: ICU, IVIG/PLEX,
high-dose steroids
Application to MMM Syndrome:
•
Most MMM patients present with MGFA
Class III-V (severe disease)[33][34]
•
MGFA Class ≥II: Strong indication for early IVIG alongside steroids[33][44]
SECTION 7: SPECIAL CONSIDERATIONS
Pyridostigmine Use in
Myocarditis
Risks:
•
Cholinergic side effects:
Bradycardia, hypotension, AV block, QT prolongation
•
12 patients required
pacemakers in Furlepa series[32]
•
3 patients developed new
conduction deficits after AChEI[32]
Mitigation
Strategies:
1.
Hold pyridostigmine until cardiac stability confirmed:
–
No high-grade AV block
–
Heart rate >60 bpm
–
Blood pressure stable
2.
Start low dose: 30 mg every 8 hours
3.
Monitor closely: Telemetry, ECG before and 1 hour after first dose
4.
If conduction worsens: Discontinue immediately
Plasma Exchange After IVIG
Problem: PLEX removes therapeutic immunoglobulins if administered shortly
after IVIG[32]
Optimal
Sequencing:
1.
PLEX first (Days 3-7) → IVIG afterward (Days 8-12)
2.
OR IVIG first → wait ≥4
weeks → PLEX if relapse[32]
Clinical
Decision:
•
If patient deteriorating
rapidly: PLEX first (faster onset: 1-2 days vs 3-5 days for IVIG)
•
If antibody-mediated
(anti-AChR+, anti-titin+): PLEX preferred
•
If complement-mediated or
steroid-refractory myositis: IVIG preferred
Steroid Tapering and Relapse
Risk of
Relapse:
•
Several cases experienced symptom
recurrence during steroid taper[32]
•
3M syndrome generally monophasic
(3.7% relapse rate)[32]
•
Relapses within 7 months
of initial episode[32]
If
Relapse Occurs:
1.
Increase steroids to previous
effective dose
2.
Resume IVIG or PLEX
3.
Consider maintenance
immunosuppression:
–
Mycophenolate mofetil 500-1000
mg BID
–
Azathioprine 1-2 mg/kg/day
–
Tocilizumab 162 mg SC weekly
4.
Do not rechallenge with ICI
Cancer Management After MMM
ICI
Rechallenge:
•
Absolutely contraindicated[32][33]
•
Risk of fatal recurrence
outweighs oncologic benefit
•
One patient rechallenged due to
cancer remission → myasthenia worsened[32]
Alternative
Systemic Therapies:
•
Targeted therapy (if driver mutations present):
–
BRAF inhibitors (melanoma)
–
EGFR inhibitors (NSCLC)
–
ALK inhibitors (NSCLC, RCC)
•
Chemotherapy
•
Radiation therapy
•
Clinical trials of non-ICI investigational agents
Multidisciplinary
Decision-Making:
•
Tumor board discussion:
Oncology, cardiology, neurology
•
Patient/family counseling: Risk
of recurrence vs cancer progression
•
Shared decision-making
SECTION 8: PROGNOSTIC FACTORS
Mortality
Predictors (Poor Prognosis)[32][33][53]
1.
Cardiac involvement severity:
–
Complete heart block,
ventricular arrhythmias
–
LVEF <40%
–
Cardiogenic shock
2.
Respiratory failure:
–
MGFA Class V (intubation)
–
Leading cause of death: 41%
died from ventilatory failure[32]
3.
Delayed diagnosis/treatment:
–
Onset to steroid initiation
>7 days
–
Delayed second-line therapy
4.
Steroid-refractory disease:
–
No improvement after 7 days of
high-dose steroids
5.
Age >70 years, multiple
comorbidities[32]
Favorable Prognostic Factors
1.
Early diagnosis and
treatment:
–
Immediate ICI discontinuation
–
High-dose steroids within 24-48
hours
–
Early IVIG (MGFA ≥II)[33][44]
2.
Antibody-positive disease (paradoxically):
–
Anti-AChR, anti-titin positive
may predict rituximab response[33]
3.
Isolated myositis or MG (without myocarditis):
–
Lower mortality than MMM triad
4.
Aggressive immunosuppression:
–
Abatacept + ruxolitinib for
myocarditis[33][51][53]
–
Rituximab for antibody-mediated
disease[33]
SECTION 9: CLINICAL PEARLS
1.
“When you see one, look for
all three”: 30-40% of irMG cases have myositis;
8-40% have myocarditis[33]. Screen all components.
2.
Normal echocardiogram does
not exclude myocarditis: Majority had preserved
LVEF[32][33]. Cardiac MRI is gold standard.
3.
Normal CK does not exclude
myositis: CK can be normal in up to 10% of
ICI-myositis cases[34]. EMG, muscle MRI, or biopsy may be needed.
4.
Troponin T > Troponin I: Troponin T more sensitive for ICI-myocarditis[32][33].
5.
Antibody-negative MG is
common: 58% of MMM cases were anti-AChR
negative[32]. Diagnosis remains clinical + EMG.
6.
Steroids alone may worsen
myasthenia: 57% worsened after steroids[32].
Consider concurrent IVIG for MGFA ≥II.
7.
PLEX timing matters: Don’t give PLEX immediately after IVIG[32]. Wait ≥4 weeks or give
PLEX first.
8.
Pyridostigmine can cause
heart block: Hold until cardiac stability
confirmed[32].
9.
ICU admission threshold is
low: 67% required ICU[32]. Admit early for
telemetry, respiratory monitoring.
10.
Mortality is high despite
treatment: 38-60% in-hospital mortality[32][33].
Aggressive early treatment may improve outcomes.
SECTION 10:
REFERENCES AND EVIDENCE BASE
This clinical guide is based on:
1.
Furlepa M, Watts I, Carr AS. Management of Triple M Syndrome: A Narrative Review of Immune
Checkpoint Inhibitor-Induced Myasthenia Gravis, Myositis and Myocarditis. Cancers.
2025;17(13):2063.
–
82 cases from systematic review
–
First review focused on
treatment strategies and outcomes
–
PRISMA-compliant methodology
2.
Sánchez-Camacho A,
Torres-Zurita A, et al. Management of
immune-related myocarditis, myositis and myasthenia gravis (MMM) overlap
syndrome: a single institution case series and literature review. Front
Immunol. 2025;16:1597259.
–
4 detailed cases from single institution
–
Focus on autoimmune
profile-guided therapy
–
Includes tocilizumab, rituximab
protocols
3.
ASCO Guideline 2021: Management of Immune-Related Adverse Events in Patients Treated
With Immune Checkpoint Inhibitor Therapy. J Clin Oncol.
2021;39(36):4073-4126.
4.
ESMO Guideline 2022: Management of toxicities from immunotherapy: ESMO Clinical
Practice Guideline. Ann Oncol. 2022;33(12):1217-1238.
5.
NCCN Guidelines 2024: Management of Immunotherapy-Related Toxicities.
6.
ESC-ICOS Guidelines 2022: Diagnostic criteria for ICI-induced myocarditis.
7.
MGFA Classification: Myasthenia Gravis Foundation of America Clinical Classification.
APPENDIX: QUICK REFERENCE CARDS
Card 1: Initial
Workup (First 24 Hours)
Labs:
•
☐ Troponin I or T (repeat
q6-12h × 3)
•
☐ CK, aldolase
•
☐ CBC, CMP
•
☐ Anti-AChR, anti-titin,
anti-MuSK antibodies
Cardiac:
•
☐ 12-lead ECG
•
☐ Continuous telemetry
•
☐ Echocardiography
Neuromuscular:
•
☐ Neurologic exam (ptosis,
diplopia, bulbar, strength)
•
☐ EMG/repetitive nerve
stimulation (if safe)
•
☐ FVC, NIF (if MG suspected)
Imaging:
•
☐ Chest X-ray
•
☐ Cardiac MRI (within 7-10
days)
•
☐ Consider muscle MRI
Consultations:
•
☐ Cardiology
•
☐ Neurology
•
☐ Rheumatology/Immunology
•
☐ ICU/Critical Care
Card 2: First-Line
Treatment Checklist
Immediate
(Hour 0):
•
☐ Stop ICI permanently
•
☐ Admit to ICU or
high-dependency unit
•
☐ Start methylprednisolone:
–
Pulse: 500-1000 mg IV daily ×
3-5 days
–
OR Standard: 1-2 mg/kg IV daily
•
☐ Start pyridostigmine 30-60 mg
PO q6-8h (if cardiac stable)
Within
24-48 Hours:
•
☐ Consider IVIG 2 g/kg over 3-5
days if:
–
MGFA Class ≥II
–
Bulbar symptoms
–
Rapidly progressive
•
☐ GI prophylaxis (PPI)
•
☐ Bone protection (calcium,
vitamin D)
•
☐ DVT prophylaxis
Card 3:
Escalation Criteria (Add Second-Line Therapy If:)
Clinical (48-72 hours):
•
☐ No improvement in strength
•
☐ Worsening bulbar symptoms
•
☐ Increasing oxygen requirement
•
☐ New arrhythmias
Laboratory:
•
☐ Troponin increasing or
plateaued
•
☐ CK >10,000 U/L or
increasing
•
☐ New transaminitis
Cardiac:
•
☐ LVEF decline >10%
•
☐ High-grade AV block
•
☐ Cardiogenic shock
Second-Line Options:
•
☐ IVIG 2 g/kg (if not already
given)
•
☐ PLEX × 5 sessions
•
☐ Tocilizumab 8 mg/kg IV
Card 4: Discharge Checklist
Clinical
Criteria:
•
☐ Troponin downtrending or
normalized
•
☐ CK <2× ULN
•
☐ No new arrhythmias × 48 hours
(off telemetry)
•
☐ Adequate oral intake, no
bulbar dysfunction
•
☐ Oxygen saturation >92% on
room air
•
☐ Able to ambulate
independently or with assistance
Discharge
Medications:
•
☐ Prednisone ___ mg daily (with
taper schedule)
•
☐ Pyridostigmine ___ mg q___
hours
•
☐ PPI (omeprazole 20 mg daily)
•
☐ Calcium 1200 mg + vitamin D
1000 IU daily
•
☐ Consider PJP prophylaxis
(trimethoprim-sulfamethoxazole DS 3×/week)
Follow-Up:
•
☐ Cardiology in 2 weeks
•
☐ Neurology in 2 weeks
•
☐ Oncology in 2-4 weeks
(discuss alternative cancer therapy)
•
☐ Repeat troponin, CK in 1 week
•
☐ Repeat ECG, echocardiography
in 4 weeks
Patient
Education:
•
☐ Warning signs of relapse
(weakness, chest pain, dyspnea)
•
☐ ICI rechallenge
contraindicated
•
☐ Steroid tapering schedule and
side effects
•
☐ Avoid live vaccines while
immunosuppressed
•
☐ Emergency contact numbers
CONCLUSION
MMM syndrome represents one of
the most severe and lethal immune-related adverse events associated with immune
checkpoint inhibitor therapy. Despite aggressive multimodal immunosuppression,
mortality remains unacceptably high at 38-60%. Early recognition, prompt
multidisciplinary management, and individualized treatment strategies based on
autoimmune profiles and predominant disease manifestations are essential to
optimize patient outcomes.
Key evidence gaps remain,
including:
•
Optimal sequencing and timing
of immunosuppressive agents
•
Predictive biomarkers for
disease severity and treatment response
•
Long-term cardiac and
neuromuscular sequelae
•
Standardized diagnostic
criteria specifically for MMM overlap syndrome
The development of consensus
guidelines, prospective registries, and randomized trials of targeted
immunosuppressive therapies (abatacept, ruxolitinib, rituximab, tocilizumab)
are urgently needed to improve the dismal prognosis of this condition.
For clinicians managing
patients on ICI therapy: Maintain a high index of suspicion, screen
comprehensively for all three components when one is suspected, and do not
hesitate to escalate treatment early and aggressively.
Disclaimer: This guide is intended for educational purposes for healthcare
professionals. Individual patient management should be tailored to specific
clinical circumstances in consultation with relevant specialists. Always refer
to the most current published guidelines and institutional protocols.
Document Version: 1.0
Date: December 25, 2025
Author: Clinical Research Team
Based on: Furlepa et al. (2025), Sánchez-Camacho et al. (2025),
ASCO/ESMO/NCCN Guidelines
